Information  X 
Enter a valid email address

Bioventix Plc (BVXP)

  Print      Mail a friend

Thursday 14 July, 2016

Bioventix Plc

Issue of Equity

Bioventix plc

(“Bioventix” or the “Company”)

Issue of Equity

Bioventix plc (AIM: BVXP) announces that it has today applied for 47,725 ordinary shares of 5 pence each (the “Option Shares”) to be admitted to trading on AIM (“Admission”). It is expected that Admission will occur and that dealings will commence in the Option Shares on 18 July 2016.

The Option Shares are being issued pursuant to the exercise of options by employees of the Company. The Option Shares will rank pari passu with the existing ordinary shares of 5 pence each in the capital of the Company ("Ordinary Shares").

The total number of Ordinary Shares in issue following Admission will be 5,098,656 and the Company holds no shares in treasury. Therefore the total number of Ordinary Shares with voting rights in the Company will be 5,098,656.

The above figure of 5,098,656 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Bioventix under the FCA’s Disclosure and Transparency Rules.

For further information please contact:

Bioventix plc
Peter Harrison

Chief Executive Officer
Tel: 01252 728 001
finnCap Ltd
Geoff Nash/Simon Hicks
Stephen Norcross

Corporate Finance
Corporate Broking
Tel: 020 7220 0500

About Bioventix plc:

Bioventix (www.bioventix.com) specialises in the development and commercial supply of high-affinity monoclonal antibodies with a primary focus on their application in clinical diagnostics, such as in automated immunoassays used in blood testing.  The antibodies created at Bioventix are generated in sheep and are of particular benefit where the target is present at low concentration and where conventional monoclonal or polyclonal antibodies have failed to produce a suitable reagent.  Bioventix currently offers a portfolio of antibodies to customers for both commercial use and R&D purposes, for the diagnosis or monitoring of a broad range of conditions, including heart disease, cancer, fertility, thyroid function and drug abuse.  Bioventix currently supplies antibody products and services to the majority of multinational clinical diagnostics companies.  Bioventix is based in Farnham, UK and its shares are traded on AIM under the symbol BVXP.


a d v e r t i s e m e n t